Browsing Tag
Eli Lilly and Company
178 posts
AstraZeneca just joined the direct-to-consumer drug race — here’s what it means for patients and rivals
AstraZeneca launches AstraZeneca Direct in the U.S. with up to 70% discounts. Explore how this direct-to-consumer model could reshape drug access.
Eli Lilly wins FDA approval for Inluriyo in ESR1-mutated metastatic breast cancer
FDA approves Eli Lilly’s Inluriyo for ESR1-mutated breast cancer, boosting oncology pipeline and investor confidence. Learn how this reshapes treatment.
Eli Lilly commits $6.5bn to new Houston manufacturing site for small molecule APIs
Eli Lilly invests $6.5B in a Houston API facility to scale orforglipron and small molecule drugs, creating 4,600+ jobs and reshaping U.S. pharma supply.
How Celltrion’s $330m Eli Lilly deal positions it for a new era of U.S. biomanufacturing
Celltrion’s $330M purchase of Eli Lilly’s U.S. plant signals a tariff-proof pivot in biosimilars, reshaping pharma manufacturing in the U.S. today.
Pfizer to buy Metsera in $7.3bn obesity drug deal, challenging Lilly and Novo
Pfizer’s $7.3B Metsera takeover could reshape the GLP-1 obesity drug race and challenge Eli Lilly and Novo Nordisk’s dominance in weight loss treatments.
GLP-1 receptor agonists show promise in cutting death and heart risk in psoriasis patients
Discover how GLP-1 drugs may slash death and heart risks in psoriasis patients, reshaping care strategies beyond skin treatment.
Why CVS Caremark’s decision to drop Zepbound could reshape the billion-dollar weight-loss drug war
CVS Caremark faces a lawsuit after dropping Eli Lilly’s Zepbound from coverage. Explore patient, investor, and payer implications in the GLP-1 market battle.
Lilly’s Verzenio hits overall survival milestone in early breast cancer after 2-year treatment
Verzenio improves survival in high-risk early breast cancer, confirms Eli Lilly. Find out how this changes the treatment landscape.
Eli Lilly lifts 2025 outlook after Zepbound and Mounjaro drive 38% Q2 revenue surge
Eli Lilly’s Q2 2025 revenue jumped 38% to $15.56 billion, led by Zepbound and Mounjaro. Read how product growth is reshaping guidance.
Lilly’s oral GLP-1 drug orforglipron cuts A1C and body weight in type 2 diabetes Phase 3 trial
Eli Lilly’s once-daily oral GLP-1 therapy orforglipron delivered significant A1C and weight reductions in Phase 3 ACHIEVE-1 trial, with safety aligned to injectables.